secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001193125-25-133745
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies shareholders approve authorized share increase to 700M
----------------------------------------------------------------------------

- Authorized common stock increased from 400M to 700M shares; approved 171.3M for, 8.2M against.
- Directors Phillip B. Donenberg and Sukumar Nagendran elected with 114.3M and 123.3M votes for, respectively.
- Deloitte & Touche ratified as independent auditor for FY2025; 179.4M votes for.
- Annual meeting turnout: 179.6M shares (~87%) of 205.1M outstanding represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525133745/0001193125-25-133745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525133745/d843671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-133745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer